Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-98633 (BMS-986354) in Relapsed/Refractory Multiple Myeloma
NCT04394650Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Aug 2020
- Primary completion
- Jul 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CC-98633 in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: Adverse Events at 2 years. Started Aug 2020; status: completed.
02
Drugs
CC-98633
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04394650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04394650.